Because mTOR contributes to age-related cellular changes, simufilam’s suppression of mTOR overactivation concurrent with improved insulin sensitivity may slow certain aging processes and attenuate this pathological feature of AD, potentially benefiting brain function and memory in AD and in aging. Here, INS is linked to Alzheimer disease.